Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects

NCT00549198 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00549198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00549198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2007
Completion date
December 31, 2009
Enrollment
392 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection, infection, human immunodeficiency virus i